Comparison of the time-to-response between radiotherapy and epidermal growth factor receptor - Tyrosine kinase inhibitors for advanced non-small cell lung cancer with EGFR mutation

Anticancer Research

Volumn 33, Issue 8, 2013, Pages 3279-3284

  Imai, Hisao ^a   Shukuya, Takehito ^a   Takahashi, Toshiaki ^a   Fujiwara, Sakae ^a   Mori, Keita ^a   Ono, Akira ^a   Akamatsu, Hiroaki ^a   Taira, Tetsuhiko ^a   Kenmotsu, Hirotsugu ^a   Naito, Tateaki ^a   Kaira, Kyoichi ^a   Murakami, Haruyasu ^a   Harada, Hideyuki ^a   Endo, Masahiro ^a   Nakajima, Takashi ^a   Yamamoto, Nobuyuki ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

Author keywords

Epidermal growth factor receptor tyrosine kinase inhibitor; Erlotinib; Gefitinib; Non small cell lung cancer; Radiotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; NAVELBINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG SENSITIVITY; FEMALE; GENE MUTATION; HISTOLOGY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; THORAX RADIOGRAPHY; TREATMENT PLANNING; TREATMENT RESPONSE;

EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR; ERLOTINIB; GEFITINIB; NON-SMALL CELL LUNG CANCER; RADIOTHERAPY;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; RADIOGRAPHY, THORACIC; RADIOTHERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; TIME FACTORS; TREATMENT OUTCOME;

EID: 84883265856     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A and Ward E: Cancer treatment and survivorship statistics, 2012. 62: 220-241, 2012.
2. Cella D, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Heyes A, Ochs JS, Wolf MK, Kay AC, Kris MG and Natale RB: Clinically meaningful improvement in symptoms and quality of life for patients with non-small cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol 23: 2946-2954, 2005.
3. Bezjak A, Tu D, Seymour L, Clark G, Trajkovic A, Zukin M, Ayoub J, Lago S, de Albuquerque Ribeiro R, Gerogianni A, Cyjon A, Noble J, Laberge F, Chan RT, Fenton D, von Pawel J, Reck M and Shepherd FA: Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 24: 3831-3837, 2006.
4. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA and Fukuoka M: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957, 2009.
5. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K and Fukuoka M: Gefitinib versus cisplatin plus docetaxel in patients with nonsmall- cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11: 121-128, 2010.
6. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S and Nukiwa T: Gefitinib or chemotherapy for non-small cell lung cancer with mutated EGFR. N Engl J Med 362: 2380-2388, 2010.
7. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009.
8. Nagai Y, Miyazawa H, Huqun, Tanaka T, Udagawa K, Kato M, Fukuyama S, Yokote A, Kobayashi K, Kanazawa M and Hagiwara K: Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 65: 7276-7282, 2005.
9. Yatabe Y, Hida T, Horio Y, Kosaka T, Takahashi T and Mitsudomi T: A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer. J Mol Diagnost 8: 335-341, 2006.
10. Inoue A, Suzuki T, Fukuhara T, Maemondo M, Kimura Y, Morikawa N, Watanabe H, Saijo Y and Nukiwa T: Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 24: 3340-3346, 2006.
11. Yoshida K, Yatabe Y, Park JY, Shimizu J, Horio Y, Matsuo K, Kosaka T, Mitsudomi T and Hida T: Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer. J Thorac Oncol 2: 22-28, 2007.
12. Tamura K, Okamoto I, Kashii T, Negoro S, Hirashima T, Kudoh S, Ichinose Y, Ebi N, Shibata K, Nishimura T, Katakami N, Sawa T, Shimizu E, Fukuoka J, Satoh T and Fukuoka M: Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: Results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer 98: 907-914, 2008.
13. Morita S, Okamoto I, Kobayashi K, Yamazaki K, Asahina H, Inoue A, Hagiwara K, Sunaga N, Yanagitani N, Hida T, Yoshida K, Hirashima T, Yasumoto K, Sugio K, Mitsudomi T, Fukuoka M and Nukiwa T: Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res 15: 4493-4498, 2009.
14. Thongprasert S, Duffield E, Saijo N, Wu YL, Yang JC, Chu DT, Liao M, Chen YM, Kuo HP, Negoro S, Lam KC, Armour A, Magill P and Fukuoka M: Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). J Thorac Oncol 6: 1872-1880, 2011.
15. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr., Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ and Kay AC: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with nonsmall cell lung cancer: A randomized trial. JAMA 290: 2149-2158, 2003.
16. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP and Baselga J: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21: 2237-2246, 2003.
17. Sekine I, Ichinose Y, Nishiwaki Y, Yamamoto N, Tsuboi M, Nakagawa K, Shinkai T, Negoro S, Imamura F, Eguchi K, Takeda K, Itoh Y, Tamura T, Saijo N and Fukuoka M: Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: Results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel. Ann Oncol 20: 1483-1488, 2009.
18. Armstrong BA, Perez CA, Simpson JR and Hederman MA: Role of irradiation in the management of superior vena cava syndrome. Int J Rad Oncol Biol Phys 13: 531-539, 1987.
19. Das AK, Sato M, Story MD, Peyton M, Graves R, Redpath S, Girard L, Gazdar AF, Shay JW, Minna JD and Nirodi CS: Nonsmall cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. Cancer Res 66: 9601-9608, 2006.
20. Ready N, Janne PA, Bogart J, Dipetrillo T, Garst J, Graziano S, Gu L, Wang X, Green MR and Vokes EE: Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGBstratified phase II trial. J Thorac Oncol 5: 1382-1390, 2010.
21. Okamoto I, Takahashi T, Okamoto H, Nakagawa K, Watanabe K, Nakamatsu K, Nishimura Y, Fukuoka M and Yamamoto N: Singleagent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor. Lung Cancer 72: 199-204, 2011.
22. Mak RH, Doran E, Muzikansky A, Kang J, Neal JW, Baldini EH, Choi NC, Willers H, Jackman DM and Sequist LV: Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC. Oncologist 16: 886-895, 2011.
23. Wilson P, Bezjak A, Asch M, Barton R, Wong R, Levin W, Kane G and Kirkbride P: The difficulties of a randomized study in superior vena caval obstruction. J Thorac Oncol 2: 514-519, 2007.